Announcement
BUHLMANN Diagnostics Corp is pleased to announce the collaboration with Beckman Coulter for a worldwide distribution of the BÜHLMANN fCAL® turbo assay & BÜHLMANN fPELA® turbo assay on their clinical chemistry AU series analyzers (AU480, AU680, AU5800, and DxC 700 AU).
What are the Benefits of this Collaboration?
Directly applying the fCAL® turbo and fPELA® turbo on Beckman analyzers streamlines testing procedures for modern core labs, providing rapid and reliable results with minimal hands-on time.
CALEX® Cap Stool Preparation Device: Additionally, combining both assays with the BÜHLMANN CALEX® Cap for Total Laboratory Automation (TLA) minimizes the complexity of sample processing (apply directly on analyzers).
How will the rollout of this collaboration be managed, especially for existing customers?
The rollout plan depends on the initiative of local Beckman Coulter affiliates. Existing customers established on those analyzers will continue to be served by BUHLMANN Diagnostics Corp.
When is the anticipated product launch happening in the US?
The product launch is scheduled for September 2024.
